Introduction
============

International studies of type 1 diabetes ,[@ref1] [@ref2] such as the DiaMond (Diabetes Mondiale) Project and European Community Concerted Action Programme in Diabetes (EURODIAB) study have shown wide variation in the incidence of type 1 diabetes among children. According to the DiaMond Project, China had one of the lowest incidences of type 1 diabetes in children---0.51 per 100 000 person years during 1985-94.[@ref3] A nationwide registry of type 1 diabetes in China does not exist.

The incidence of type 1 diabetes in children has been increasing worldwide.[@ref2] [@ref4] [@ref5] Recent results of the SEARCH for Diabetes in Youth study from the United States suggest that environmental or behavioural factors, or both, play larger parts in the increased incidence of type 1 diabetes compared with decades ago.[@ref5] [@ref6] The study of type 1 diabetes in a low incidence region such as China may help advance the understanding of the contribution of varying combinations of genetic and environmental factors to the development of the disease. Moreover, most epidemiological studies of type 1 diabetes focused on childhood onset type 1 diabetes. Although type 1 diabetes most often develops in children, it can occur at any age.[@ref7] [@ref8] Our previous study also indicated that the onset of type 1 diabetes in adulthood is not rare in China.[@ref9] Yet little is known about its incidence in adults aged more than 20 years.[@ref10]

We carried out a nationwide, population based registry study (the Epidemiological Study of Type 1 Diabetes Mellitus in China (T1D China)) to investigate the incidence of type 1 diabetes in all age groups in China during 2010-13.

Methods
=======

Our study is a population based multicentre observational study, with ascertainment of doctor diagnosed cases of type 1 diabetes. We identified new cases occurring during 2010 to 2013 in the resident population of 13 areas across China (Harbin, Shenyang, Beijing, Shanghai, Nanjing, Jinan, Wuhan, Changsha, Guangzhou, Chengdu, Xi'an, Lanzhou, Yinchuan; [fig 1](#f1){ref-type="fig"}, and see supplementary table S1).
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Study population
----------------

Our study population comprised residents of 13 study areas. These areas were chosen from the seven administrative regions of China (northeast, north, northwest, southwest, central, east, and south) according to geographical location, climate, culture, ethnicity, and population, and they are representative of the seven administrative regions. We selected at least one area from each of these administrative regions. Besides, a huge imbalance in population density exists in China: more than 90% of the population reside in the southeast. We also ensured that there was at least one study area every 5° of latitude (fig 1, and see supplementary table S1). In some of the administrative regions we therefore selected one or two additional areas. The study areas also consist of regions of different economic development levels, as represented by the gross domestic product in 2010.[@ref11] The study areas covered the less developed, moderately developed, and well developed areas in China.

The study population (denominator) included residents of all ages in the 13 study areas during 2010 to 2013. According to the 2010 Chinese census,[@ref12] we defined the resident population as: people whose registered address agreed with their primary address and who had stayed at their primary address for six months or more; people whose registered address disagreed with their primary address, but who had stayed at their primary address for six months or more; people whose registered address disagreed with their primary address, but who had stayed at their primary address for less than six months; and people in active military service and those whose primary address could not be specified---they were not included in the resident population.

The 2010 Chinese census[@ref12] conducted by the National Bureau of Statistics of China provides precise information on China's mainland population, which is essential for the calculation of the denominator in a nationwide registry study. Our study period was 1 January 2010 to 31 December 2013, which allowed at least 18 months of a diagnostic time window for cases to be included in our study when we started the onsite data validation and inspection (see supplementary materials, section 4) in June 2015. We estimated the denominator yearly according to the 2010 Chinese census and annual government reports on natural population growth (see supplementary materials, section 2). Derivation of appropriate denominators is a multistep process, adjusted for sex categorisation and the natural growth rate of the local population. Our study population covered more than 133 million person years at risk between 2010 and 2013, which represents approximately 10% of the Chinese population, including 6% of those aged less than 15 years. This provided enough power to estimate the incidence over 1.0 per 100 000 person years.

The numerator included all newly diagnosed cases of type 1 diabetes in the resident population in the study areas from 1 January 2010 to 31 December 2013.

Data sources and collection
---------------------------

The data coordinating service provider collected and submitted data from four sources: the medical record databases from all the hospitals providing diabetes care in the 13 study areas (505 hospitals); outpatient based pharmacies in tertiary hospitals in the 13 areas (228 hospitals); government medical insurance databases; and patient self reports from online and offline communities of patients with diabetes spontaneously founded and maintained by patients with diabetes or their family members, or both, which were confirmed by medical records (see supplementary materials, section 2).

Collected data included identification markers and clinical information. Identification markers included mandatory and optional markers. For all validated cases, mandatory markers, including initials of each Chinese character of the name, sex, date of birth, registered address, primary address, date of diabetes diagnosis, date of insulin treatment initiation, hospitals where treated (with inpatient or outpatient status, or both, specified), and ethnicity, were collected, usually as part of the case validation process. For cases from communities of patients with diabetes, we collected mandatory information from the hospital where diabetes was first diagnosed. We excluded cases with missing mandatory information after onsite validation. Supplementary materials section 2 lists the optional markers. Clinical information was collected from medical record databases, as part of the case ascertainment process, including clinical presentations at onset (symptoms, occurrence of diabetic ketosis or ketoacidosis), family history, treatment for hyperglycaemia, C peptide level at onset or within 12 months after diagnosis, and presence of diabetes autoantibodies at any time.

The data coordinating service provider registered and anonymised the cases and sent the information to the data management committee. Mandatory information was available in 98.8% of cases. Data managers used identification markers for matching within the same source and across sources to identify potential duplicate records at area level (see supplementary materials, section 3, part 4)

Case ascertainment
------------------

Participating endocrinologists or paediatricians, or both, or an expert committee on type 1 diabetes established the diagnosis (see supplementary materials, section 1). The clinical diagnosis of type 1 diabetes was based on the American Diabetes Association descriptions of type 1 diabetes[@ref8] and the World Health Organization reports on the classification of diabetes.[@ref13] Diabetic ketoacidosis was defined based on guidelines[@ref14] [@ref15] and data accessibility in China. Diabetic ketoacidosis was diagnosed in people with the following history and laboratory results: hyperglycaemia (glucose \>11.1 mmol/L) or known diabetes ; ketonemia: raised levels of blood ketobodies as judged by participating investigators, or important ketonuria (\>++ on standard urine dipsticks); and acidemia: bicarbonate (HCO3^-^) \<15.0 mmol/L or venous pH \<7.3, or both.

Data managers examined all submitted information to identify participants with an uncertain diagnosis of type 1 diabetes. Uncertain results were sent back to the data coordinating service provider. This provider required the corresponding investigator to feedback on the diagnosis of type 1 diabetes and provide any previously absent data related to the diagnosis if available. The corresponding investigator would make the judgment of diagnosis based on the currently available data, and would follow-up the patient if necessary and then give feedback to the data coordinating service provider. We ensured that the diagnostic time window would be no less than 18 months for participants, as a report shows that 18 months is the usual duration from the time a patient first sees a doctor to the final diagnosis.[@ref16] The data coordinating service provider informed the data managers of the feedback. Any cases of uncertain diagnosis were submitted to the expert committee for final judgment. We ascertained all cases with a final diagnosis of type 1 diabetes (see supplementary materials, section 3).

Statistical analysis
--------------------

To assess the completeness of case ascertainment we used the capture mark recapture method[@ref17] and a two-mode ascertainment model (see supplementary materials, section 5). We defined the percentage of completeness of ascertainment for each study area as the number of observed cases divided by the number estimated from the capture mark recapture method. Incidence by age group, sex, and area were calculated per 100 000 person years at risk, and we calculated 95% confidence intervals based on inverting the score test for a binomial proportion.[@ref18] The model to estimate the national incidence of type 1 diabetes in China was developed from data collected in the 13 study areas and based on a Poisson distribution, in which factors potentially affecting the incidence of type 1 diabetes were added as covariates (see supplementary materials, section 6). Pearson's χ^2^ analysis was applied to comparison of rates. Spearman correlation was used to analyse the relation between incidence and potentially related factors. For all statistical analyses we used SAS version 9.4 (SAS Institute, Cary, NC). We considered P\<0.05 to be statistically significant.

Patient involvement
-------------------

No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for recruitment, design, or implementation of the study. No patients were asked to advise on interpretation or writing up of results. However, patient self reports were collected from online and offline communities of patients with diabetes spontaneously founded and maintained by patients with diabetes or their family members, or both. We contacted the founders and the people currently in charge of these communities and released a questionnaire asking for members of these communities to volunteer to self report. No patient or their family members were involved in the design of such a questionnaire, and the information collected from the questionnaire was anonymised. There are no plans to disseminate the results of the research to study participants.

Results
=======

Our study population comprised 5018 people with type 1 diabetes newly diagnosed between 2010 and 2013 ([fig 2](#f2){ref-type="fig"}): 1239 were aged 0-14 years, 1799 were aged 15-29 years, and 1980 were aged ≥30 years, and 2755 (54.9%) were male. [Table 1](#tbl1){ref-type="table"} summarises the number of participants and the estimated annual incidence in each study area. Completeness of ascertainment was estimated to be more than 95% across the 13 areas. Completeness was relatively even among age groups, at 99.3% in the 0-14 years group, 98.4% in the 15-29 years group, and 98.8% in the ≥30 years group. (see supplementary table S3).
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###### 

Incidence of type 1 diabetes in different age groups in 13 areas of China

  Study area   Latitude (°N)   No of cases   Total No of cases   Incidence per 100 000 person years (95% CI)                                                                            
  ------------ --------------- ------------- ------------------- --------------------------------------------- ------ --------------------- --------------------- --------------------- ---------------------
  Harbin       45.8            179           265                 190                                           634    3.59 (3.1 to 4.16)    2.43 (2.16 to 2.75)   0.75 (0.65 to 0.87)   1.54 (1.42 to 1.66)
  Shenyang     41.8            96            123                 118                                           337    2.48 (2.03 to 3.03)   1.44 (1.21 to 1.72)   0.58 (0.48 to 0.69)   1.03 (0.92 to 1.14)
  Beijing      39.9            232           245                 263                                           740    2.46 (2.16 to 2.79)   1.08 (0.95 to 1.22)   0.53 (0.47 to 0.6)    0.91 (0.84 to 0.97)
  Yinchuan     38.5            23            31                  14                                            68     2.43 (1.62 to 3.65)   0.14 (0.1 to 0.19)    0.03 (0.02 to 0.05)   0.98 (0.78 to 1.25)
  Jinan        36.7            77            73                  59                                            209    2.18 (1.75 to 2.73)   0.99 (0.78 to 1.24)   0.35 (0.27 to 0.46)   0.76 (0.66 to 0.87)
  Lanzhou      36.0            40            77                  106                                           223    2.22 (1.63 to 3.03)   0.71 (0.57 to 0.88)   0.42 (0.35 to 0.51)   1.57 (1.38 to 1.79)
  Xi'an        34.3            78            107                 115                                           300    1.82 (1.46 to 2.27)   1.13 (0.93 to 1.36)   0.56 (0.47 to 0.68)   0.88 (0.79 to 0.98)
  Nanjing      32.1            85            115                 135                                           335    2.23 (1.8 to 2.75)    1.28 (1.06 to 1.53)   0.69 (0.58 to 0.81)   1.03 (0.93 to 1.15)
  Shanghai     31.1            130           236                 417                                           783    1.19 (1.00 to 1.42)   0.92 (0.81 to 1.05)   0.72 (0.65 to 0.79)   0.83 (0.77 to 0.89)
  Chengdu      30.7            78            104                 114                                           296    1.14 (0.91 to 1.42)   0.69 (0.57 to 0.83)   0.33 (0.27 to 0.4)    0.52 (0.47 to 0.59)
  Wuhan        30.5            77            171                 186                                           434    1.61 (1.29 to 2.02)   1.51 (1.30 to 1.75)   0.77 (0.67 to 0.89)   1.08 (0.98 to 1.19)
  Changsha     28.2            47            53                  81                                            181    1.29 (0.97 to 1.72)   0.69 (0.53 to 0.9)    0.47 (0.38 to 0.59)   0.64 (0.55 to 0.73)
  Guangzhou    23.2            97            199                 182                                           478    1.55 (1.27 to 1.9)    1.36 (1.19 to 1.57)   0.6 (0.52 to 0.7)     0.94 (0.86 to 1.03)
  Total                        1239          1799                1980                                          5018   1.90 (1.80 to 2.01)   1.02 (0.98 to 1.07)   0.51 (0.49 to 0.53)   0.93 (0.90 to 0.95)

After adjustment for the denominator of annual change in population between 2010 and 2013, the overall estimated incidence of type 1 diabetes per 100 000 person years for all ages in the 13 study areas was 0.93 (95% confidence interval 0.90 to 0.95). There was a slight difference (P\<0.001, χ^2^=30.43) between males (0.95 per 100 000 person years, 0.91 to 0.99) and females (0.81 per 100 000 person years, 0.78 to 0.85; [table 2](#tbl2){ref-type="table"}). The incidence (per 100 000 person years) by age group was 1.90 (95% confidence interval 1.80 to 2.01) for 0-14 years, 1.02 (0.98 to 1.07) for 15-29 years, and 0.51 (0.49 to 0.53) for ≥30 years. The incidence per 100 000 person years among the 0-14 years group was 1.72 (1.58 to 1.86) among males and 2.21 (2.05 to 2.39) among females (P\<0.001, χ^2^=19.58). The incidence per 100 000 person years among the population aged ≥15 years was 0.92 (0.89 to 0.96) among males and 0.70 (0.67 to 0.74) among females (P\<0.001, χ^2^=68.22).

###### 

Incidence of type 1 diabetes in different age groups in 13 areas of China

  Variables            No of cases with type 1 diabetes   Population denominator (adjusted person years)\*   Incidence rate per 100 000 person years (95% CI)
  -------------------- ---------------------------------- -------------------------------------------------- --------------------------------------------------
  Total                5018                               1 35 408 192.0                                     0.93 (0.90 to 0.95)
  Age group (years):                                                                                         
   0-4                 251                                5 703 458.3                                        1.10 (0.97 to 1.24)
   5-9                 416                                5 241 315.0                                        1.98 (1.80 to 2.18)
   10-14               572                                5 326 180.4                                        2.68 (2.47 to 2.91)
   15-19               501                                8 736 839.1                                        1.43 (1.31 to 1.56)
   20-24               668                                15 087 517.4                                       1.11 (1.03 to 1.19)
   25-29               630                                13 181 805.9                                       1.19 (1.11 to 1.29)
   30-34               489                                11 940 293.3                                       1.02 (0.94 to 1.12)
   35-39               362                                12 447 614.5                                       0.73 (0.66 to 0.81)
   40-44               280                                12 972 355.0                                       0.54 (0.48 to 0.61)
   45-49               246                                11 461 933.4                                       0.54 (0.47 to 0.61)
   50-54               197                                8 241 801.7                                        0.60 (0.52 to 0.69)
   55-59               176                                8 160 777.1                                        0.54 (0.47 to 0.62)
   60-64               99                                 5 648 184.5                                        0.44 (0.36 to 0.53)
   65-69               57                                 3 732 342.8                                        0.38 (0.29 to 0.49)
   70-74               39                                 3 083 024.2                                        0.32 (0.23 to 0.43)
   ≥75                 35                                 2 370 583.5                                        0.37 (0.27 to 0.51)
  Male                 2755                               290 196 506                                        0.95 (0.91 to 0.99)
  Female               2263                               27 8391 771                                        0.81 (0.78 to 0.85)
  Boys \<15 years      586                                34 082 195                                         1.72 (1.58 to 1.86)
  Girls \<15 years     653                                29 531 351                                         2.21 (2.05 to 2.39)

Estimated according to population data from 2010 to 2013.

The estimated incidence of type 1 diabetes per 100 000 persons years for all ages varied from 0.52 (0.47 to 0.59) in Chengdu to 1.57 (1.38 to 1.79) in Lanzhou. For the 0-14 years group, the estimated incidence per 100 000 persons years varied from 1.14 in Chengdu (0.91 to 1.42) to 3.59 in Harbin (3.1 to 4.16). The incidence in the 0-14 years group was positively correlated with latitude (*r*=0.88, P\<0.001). The estimated incidence per 100 000 person years for the 15-29 years group varied from 0.14 in Yinchuan (0.1 to 0.19) to 2.43 in Harbin (2.16 to 2.75) and for the ≥30 years group varied from 0.03 in Yinchuan (0.02 to 0.05) to 0.77 in Wuhan (0.67 to 0.89). The latitude related correlations were not observed in the last two age groups (15-29 years: *r*=0.49, P=0.09; ≥30 years: *r*=0.03, P=0.92) (see supplementary table S4).

[Table 2](#tbl2){ref-type="table"} summarises the incidence of type 1 diabetes in the different age groups. Among the under 15s, the incidence peak was observed in the 10-14 years group (incidence per 100 000 person years 1.10 (0.97 to 1.24), 1.98 (1.80 to 2.18), 2.68 (2.47 to 2.91), for age groups 0-4 years, 5-9 years, and 10-14 years, respectively). For groups aged more than 15 years, the incidence of type 1 diabetes decreased steadily with age (P\<0.001, χ^2^=989.54).

Based on previous reports[@ref19] [@ref20] [@ref21] [@ref22] [@ref23] on factors affecting the incidence of type 1 diabetes and data availability, we performed correlation analysis and revealed that age group, latitude, and exposure to sunlight (as represented by average peak sunlight time (kWh/m^2^/day)) was statistically significantly correlated with incidence (see supplementary materials, section 6). Using a Poisson model including these three factors as covariates and population size as weight, the annual incidence of type 1 diabetes across China based on the 13 study areas was 1.01 (0.18 to 1.84) per 100 000 person years. The incidence rates for ages 0-14 years, 15-29 years, and ≥30 years were 1.93 (0.83 to 3.03), 1.28 (0.45 to 2.11), and 0.69 (0.00 to 1.51) per 100 000 person years, respectively.

[Table 3](#tbl3){ref-type="table"} summarises the characteristics of type 1 diabetes at diagnosis in different age groups from medical record databases. Overall, 4661 new cases of type 1 diabetes were ascertained from medical record databases, including 1143 people aged 0-14 years, 1664 aged 15-29 years, and 1854 aged ≥30 years. Insulin treatment was started immediately in 98.4% of participants in the 0-14 years group, 93.5% in the 15-29 years group, and 91.5% in the ≥30 years group (P\<0.001, *χ^2^=*59.76). The incidence rates of diabetic ketosis and diabetic ketoacidosis within six months of diagnosis were highest among the 0-14 years group (92.9%/51.4%), followed by the 15-29 years group (89.0%/43.0%), and lowest in the ≥30 years group (83.8%/30.8%) (diabetic ketosis: P\<0.001, χ^2^=57.71; diabetic ketoacidosis: P\<0.001, χ^2^=125.72). The proportions of cases with non-detectable fasting C peptide levels (\<0.2 ng/mL) differed among the three age groups (22.5% *v* 21.7% *v* 27.5%, P=0.001, χ^2^=13.88). Data were collected on diabetes autoantibodies, including glutamate decarboxylase, the insulin antigen 2, islet cell antibody, insulin antibody, and the zinc transporter 8, tested under standardised procedures. The proportion of patients with at least one positive test result for diabetes autoantibodies showed a non-significant tendency to decrease with age (0-14 years (73.5%), 15-29 years (59.5%), ≥30 years (55.4%), P=0.22, χ^2^=3.16).

###### 

Clinical characteristics of participants with onset of type 1 diabetes

  Characteristics                                                 No of cases with information available   Overall %   No (%)                      
  --------------------------------------------------------------- ---------------------------------------- ----------- ------------- ------------- -------------
  Total                                                           4661                                     100.0       1143 (24.5)   1664 (35.7)   1854 (39.8)
  Immediate initiation of insulin treatment at onset              4659                                     93.9        1125 (98.4)   1555 (93.5)   1696 (91.5)
  Diabetic ketosis \<6 months of diagnosis\*                      4652                                     87.7        1028 (92.9)   1415 (89.0)   1638 (83.8)
  Diabetic ketoacidosis \<6 months of diagnosis\*                 4453                                     40.1        546 (51.4)    694 (43.0)    547 (30.8)
  At least one positive result for DAA \<6 months of diagnosis†   173                                      60.7        25 (73.5)     44 (59.5)     36 (55.4)
  Fasting C peptide ≤0.2 ng/mL                                    3475                                     24.4        191 (22.5)    245 (21.7)    411 (27.5)

DAA=diabetes autoantibody.

Two deaths were identified in all eligible cases from medical record databases. Both were caused by diabetic ketoacidosis.

DAAs including glutamate decarboxylase, the insulin antigen 2, islet cell antibody, insulin antibody, and the zinc transporter 8, were measured by radiobinding assay confirmed by the islet autoantibody standardization programme at the First Affiliated Hospital of Nanjing University or the Second Xiangya Hospital of Central South University.

Discussion
==========

China remains one of the countries with the lowest incidence of type 1 diabetes. In our study from 2010 to 2013 we found that although type 1 diabetes tends to develop in children, most of the new cases are diagnosed in adults. Furthermore, higher latitude is correlated with a higher incidence of type 1 diabetes in under 15s, but not in older population groups. We also noticed a high prevalence of diabetic ketoacidosis in participants ascertained within six months of diagnosis during our study period.

Low incidence of type 1 diabetes in China
-----------------------------------------

Our study confirms that the incidence of type 1 diabetes remains low in China, even after the 3.8-fold increase of what was reported by the DiaMond Project two decades ago. Although the underlying mechanism is not completely known, the low incidence in China is probably attributed to genetic, environmental, and behavioural factors. A difference in prevalence of type 1 diabetes associated human leucocyte antigen genotypes has been reported to attribute to the difference in susceptibility to type 1 diabetes.[@ref24] However, other genes and environmental factors could also have an influence. Our study population has a homogenous gene background: a population of Han people. Intriguingly, when we compared the northern areas with the southern areas we observed up to a threefold difference in incidence of type 1 diabetes in the 0-14 years group. Finland is a country of high latitude (around 60.1°N), which may contribute to a higher incidence of type 1 diabetes. But if we compare the incidence in Finland[@ref25] with that in Harbin in northern China (45.8°N), it is still much lower (64.9 *v* 3.59 per 100 000 person years). This suggests that other factors, such as genetics, play a more important role in the incidence of type 1 diabetes.

Age and incidence
-----------------

In our study the incidence of type 1 diabetes in under 15s during 2010 and 2013 was 1.93 (95% confidence interval 0.83 to 3.03) per 100 000 person years, presenting a 3.8-fold increase over that reported by the DiaMond study[@ref3] in the 1990s, equal to a roughly 6.5% annual increase. This increase appears to be rapid compared with those reported by the EURODIAB (3.3%)[@ref26] and SEARCH (1.8%) studies.[@ref5] However, we did not measure the trends in incidence. In fact we compared our results with the incidence reported in China in 1998.[@ref3] These results were from part of the DiaMond study, which may be underestimated as a result of incomplete ascertainment, as some of the participating centres reported small case numbers. Thus the apparent increase should be interpreted with caution. China remains one of the countries with the lowest incidence of type 1 diabetes globally, despite the increasing trend. None the less, considering its large population, China has the largest estimated number of new annual cases of type 1 diabetes in children, at 4271 of the estimated 10 000 in the West-Pacific region in 2015.[@ref27]

In our study we found that most new cases of type 1 diabetes presented in adulthood. Indeed, approximately 65.3% of newly diagnosed cases were in participants aged more than 20 years. Our estimates for incidence of type 1 diabetes for all ages is 1.01 per 100 000 person years, and the incidence in the study areas for ages 20-29 years was 1.15 per 100 000 person years. Previous reported nationwide incidence rates at ages 20-29 years varies from 3.4 (Iran, 1990-94)[@ref28] to 19.4 (Kronoberg, Sweden, 1998-2001)[@ref29] globally. Although the paucity of type 1 diabetes incidence among all age groups makes comparison with other studies difficult, our estimates in both children and adults in China were among the lowest reported in the world. Nevertheless, we estimate that 9605 new cases occur annually in the population aged 15 or more years in China. This finding highlights the importance of the care of people with adult onset type 1 diabetes and that more resources should be provided to improve the care of this age group.

The age distribution of incidence of type 1 diabetes showed that the age of onset increases during childhood and then steadily decreases towards adulthood ([table 2](#tbl2){ref-type="table"}). The incidence rose to a peak of 2.68 per 100 000 person years in the 10-14 years group, consistent with rates reported by the DiaMond Project,[@ref1] the USA,[@ref5] and Japan[@ref30] in different periods. Most epidemiology studies that reported incidence in both childhood and adult type 1 diabetes observed the peak appearing close to puberty. However, studies from the USA[@ref31] and Europe[@ref32] described bimodal incidences, with the first peak in ages 10-14 years and the second peak around age 50 years. Such a peak around age 50 years was not observed in our study.

Sex and incidence
-----------------

Our data show that the incidence of type 1 diabetes was higher among girls aged 0-14 years, consistent with previous reports. Two international type 1 diabetes registries (EURODIAB and DiaMond)[@ref2] [@ref4] showed that the overall sex ratio for incidence of type 1 diabetes is roughly equal in children, with a minor excess in males in regions with a high incidence (populations of European origin) and an excess in females in regions with a low incidence (populations of non-European origin) such as Asia and Africa. Several reports[@ref33] [@ref34] [@ref35] indicate an excess in males among adults in populations of European origin. In contrast with the incidence of type 1 diabetes in children where an excess in girls was observed, we found that the incidence of type 1 diabetes in the population aged ≥15 years was greater in men than in women, consistent with previous findings. Different effects of environmental risk factors and lifestyle on incidence of type 1 diabetes in females and males were possible explanations for this difference.[@ref33] Such a difference may also suggest that childhood onset and adult onset type 1 diabetes have different manifestations in the sexes.

Latitude and incidence
----------------------

Our results showed that the incidence of type 1 diabetes among children aged 0-14 years was strongly correlated with latitude, with higher rates in the north and lower in the south, but such correlation was not observed in participants aged ≥15 years. Previously reported effects of latitude on incidence of type 1 diabetes among young people are inconsistent. The EURODIAB study reported that the incidence of type 1 diabetes in childhood was positively correlated with latitude,[@ref36] whereas the SEARCH study did not show similar trends.[@ref37] The correlation between latitude and incidence in the younger but not the older population has not been reported previously. The difference between childhood onset and adult onset type 1 diabetes regarding the latitude effects on incidence may suggest different triggers for these two disease forms.

Although gene pools of the populations, ultraviolet radiation level in different regions, and the prevalence of virus infections have been postulated to be responsible for the correlation between latitude and incidence of type 1 diabetes among under 15s,[@ref19] the actual mechanism remains controversial. It has been reported that the Han population could be divided into three regional groups (northern, central, and southern) by variance in several loci of single nucleotide polymorphisms, including some in the human leucocyte antigen region previously reported to be related to psoriasis.[@ref38] Although the association between this variance and the development of type 1 diabetes is yet unknown, it is worthy of further study to clarify whether such variance is related to the incidence of type 1 diabetes.

Prevalence of diabetic ketoacidosis in cases of type 1 diabetes
---------------------------------------------------------------

Compared with other studies, ranging from no more than 15% (Sweden) to around 30% (the SEARCH study and the EURODIAB study) in young people with a diagnosis of diabetes,[@ref39] we observed a relatively high prevalence of diabetic ketoacidosis (40.1% in all age groups and 51.4% in under 15s) in participants with newly diagnosed type 1 diabetes during the study period. We collected the data on diabetic ketoacidosis occurring within six months of diagnosis. These episodes of diabetic ketoacidosis might occur at onset or after onset, reflecting different situations. Occurrence at onset of type 1 diabetes could be attributed to the acute onset of the disease or to the lack of awareness of the signs or symptoms of the disease by patients or healthcare providers. Diabetic ketoacidosis after onset but within six months of diagnosis could have been the result of insufficient education of the participant about diabetes or missing an injection of insulin. The high prevalence of diabetic ketoacidosis within six months of a diagnosis of type 1 diabetes in our study indicates that more effort and resources are needed to achieve earlier diagnosis, raise awareness, and improve education about type 1 diabetes in China.

Strengths and weaknesses of this study
--------------------------------------

We report the first population based registry study of incidence of type 1 diabetes in China in the past two decades. Our study is also the first nationwide study to provide incidence rates for type 1 diabetes in all age groups, covering a vast geographical area. These results should not only update the global map of type 1 diabetes in childhood, but also fill in the blank about the incidence of adult onset type 1 diabetes.

It has been a huge challenge to ascertain cases of type 1 diabetes. Although we were not able to utilise all the data from the medical insurance system owing to the inability to distinguish people with type 1 diabetes from those with type 2 diabetes, we had established a pharmacy based registry system and had utilised self report data from communities of patients with diabetes. Therefore, we believe that we have given as accurate an estimation as possible.

Several weaknesses of our study should be considered. The population we covered would provide enough power to estimate the incidence over 1.0 per 100 000 person years, but for the exceedingly low incidence rate of adult onset type 1 diabetes, especially in groups aged more than 40 years, a larger study population would be required to give a more accurate estimate. The study areas have a higher proportion of urban populations than that of the whole nation. This hindered us from studying the association between incidence of type 1 diabetes and environmental factors. However, correlation analysis showed no statistically significant association between incidence and the proportion of urban population (see supplementary table S4). Like most of the epidemiological studies in type 1 diabetes, the diagnosis in our study was a clinical one. We adopted a search strategy based on ICD (international classification of diseases, ninth and 10th revisions) codes and the diagnosis largely relied on our participating endocrinologists and paediatricians (see supplementary materials, section 3). This could result in missing cases or misdiagnosis. However, we took multiple steps to minimise such a possibility. We included all cases of diabetes in under 15s regardless of classification and diabetes coded as "unclassified" in all age participants when we searched with ICD codes to avoid any missing cases. Clinical information (presence of diabetes related symptoms, incidence of diabetic ketosis or diabetic ketoacidosis within six months of diagnosis, etc), and laboratory test results (including C peptide level and diabetic autoantibodies) were collected when available to assist the diagnosis. Finally, we ensured that the diagnostic time window for cases included in our study was no less than 18 months.

Conclusions
-----------

We found a rapid increase in the incidence of type 1 diabetes in under 15s in the past two decades in China, a country with a low incidence for this disease. We estimated that more than 13 000 new cases of type 1 diabetes occur every year in China, with more than 9000 in people aged 15 or more. Furthermore, we found that the incidence of type 1 diabetes was positively associated with higher latitude in under 15s, but not in the older population.

### What is already known on this topic

1.  The only available data on incidence of type 1 diabetes in China was provided by the DiaMond Project, reporting 0.51 and 0.59 per 100 000 person years among under 15s in 1985-94 and 1988-96, respectively

2.  Most epidemiological studies worldwide have focused on onset of type 1 diabetes in childhood

3.  A paucity of information thus exists on incidence of type 1 diabetes spanning all ages

### What this study adds

1.  The estimated incidence of type 1 diabetes per 100 000 persons years was 1.93 for 0-14 years, and 1.01 for all ages. Most new cases of type 1 diabetes in China are in adults

2.  The incidence rates in under 15s were positively correlated with latitude

3.  More resources should be provided to improve the care of people with onset of type 1 diabetes in adulthood
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